» Articles » PMID: 31952299

Aptamer-Conjugated Superparamagnetic Ferroarabinogalactan Nanoparticles for Targeted Magnetodynamic Therapy of Cancer

Abstract

Nanotechnologies involving physical methods of tumor destruction using functional oligonucleotides are promising for targeted cancer therapy. Our study presents magnetodynamic therapy for selective elimination of tumor cells in vivo using DNA aptamer-functionalized magnetic nanoparticles exposed to a low frequency alternating magnetic field. We developed an enhanced targeting approach of cancer cells with aptamers and arabinogalactan. Aptamers to fibronectin (AS-14) and heat shock cognate 71 kDa protein (AS-42) facilitated the delivery of the nanoparticles to Ehrlich carcinoma cells, and arabinogalactan (AG) promoted internalization through asialoglycoprotein receptors. Specific delivery of the aptamer-modified FeAG nanoparticles to the tumor site was confirmed by magnetic resonance imaging (MRI). After the following treatment with a low frequency alternating magnetic field, AS-FeAG caused cancer cell death in vitro and tumor reduction in vivo. Histological analyses showed mechanical disruption of tumor tissues, total necrosis, cell lysis, and disruption of the extracellular matrix. The enhanced targeted magnetic theranostics with the aptamer conjugated superparamagnetic ferroarabinogalactans opens up a new venue for making biocompatible contrasting agents for MRI imaging and performing non-invasive anti-cancer therapies with a deep penetrated magnetic field.

Citing Articles

Engineering Stimuli-Responsive Materials for Precision Medicine.

Zheng R, Yu C, Yao D, Cai M, Zhang L, Ye F Small. 2024; 21(1):e2406439.

PMID: 39444066 PMC: 11707583. DOI: 10.1002/smll.202406439.


Rational Design of Pectin-Chitosan Polyelectrolyte Nanoparticles for Enhanced Temozolomide Delivery in Brain Tumor Therapy.

Silantev V, Belousov A, Trukhin F, Struppul N, Shmelev M, Patlay A Biomedicines. 2024; 12(7).

PMID: 39061967 PMC: 11273711. DOI: 10.3390/biomedicines12071393.


Vincristine-based nanoformulations: a preclinical and clinical studies overview.

Shukla R, Singh A, Singh K Drug Deliv Transl Res. 2023; 14(1):1-16.

PMID: 37552393 PMC: 10746576. DOI: 10.1007/s13346-023-01389-6.


Magnetic Nanoscalpel for the Effective Treatment of Ascites Tumors.

Zamay T, Zamay S, Luzan N, Fedotovskaya V, Masyugin A, Zelenov F J Funct Biomater. 2023; 14(4).

PMID: 37103269 PMC: 10145876. DOI: 10.3390/jfb14040179.


Development of DNA aptamers for visualization of glial brain tumors and detection of circulating tumor cells.

Kichkailo A, Narodov A, Komarova M, Zamay T, Zamay G, Kolovskaya O Mol Ther Nucleic Acids. 2023; 32:267-288.

PMID: 37090419 PMC: 10119962. DOI: 10.1016/j.omtn.2023.03.015.


References
1.
Muharemagic D, Labib M, Ghobadloo S, Zamay A, Bell J, Berezovski M . Anti-Fab aptamers for shielding virus from neutralizing antibodies. J Am Chem Soc. 2012; 134(41):17168-77. DOI: 10.1021/ja306856y. View

2.
Engelberg S, Modrejewski J, Walter J, Livney Y, Assaraf Y . Cancer cell-selective, clathrin-mediated endocytosis of aptamer decorated nanoparticles. Oncotarget. 2018; 9(30):20993-21006. PMC: 5940367. DOI: 10.18632/oncotarget.24772. View

3.
Belyanina I, Zamay T, Zamay G, Zamay S, Kolovskaya O, Ivanchenko T . Cancer Cells Elimination Guided by Aptamer-Functionalized Gold-Coated Magnetic Nanoparticles and Controlled with Low Frequency Alternating Magnetic Field. Theranostics. 2017; 7(13):3326-3337. PMC: 5595135. DOI: 10.7150/thno.17089. View

4.
Gaus M, Goez A, Elstner M . Parametrization and Benchmark of DFTB3 for Organic Molecules. J Chem Theory Comput. 2015; 9(1):338-54. DOI: 10.1021/ct300849w. View

5.
Ridi F, Bonini M, Baglioni P . Magneto-responsive nanocomposites: preparation and integration of magnetic nanoparticles into films, capsules, and gels. Adv Colloid Interface Sci. 2013; 207:3-13. DOI: 10.1016/j.cis.2013.09.006. View